Method for reducing hyperactive gag reflex in dental treatment
|
Method for stimulating spinal cord regeneration with genetically modified human umbilical cord blood cells / 2521225 What is presented is a method for stimulating the post-traumatic spinal cord regeneration consisting in a single-stage transplantation of human umbilical cord blood mononuclear cells pre-transduced with recombinant adenovirus with a cloned gene of glial derived neurotrophic factor (gdnf), in the damage area. |
|
Pharmaceutical compositions for dehydration, atrophy and removal of abnormal tissues / 2520754 Invention refers to the pharmaceutical industry, particularly to a pharmaceutical composition for dehydration, atrophy and removal of abnormal tissues, and to using it. The pharmaceutical composition for dehydration, atrophy and removal of abnormal tissues contains a composite of an inorganic polymer iron salt as an active ingredient; the composite of the inorganic polymer iron salt is polymer ferrous sulphate silicate (PFSS), or polyferrous silicate chloride (PFSC), or polyphosphate ferrous sulphate (PPFS). Using the pharmaceutical composition consists in preparing the drug for dehydration, atrophy and removal of abnormal tissues. |
 Method (versions) and preparation for modification of eating behaviour / 2519748Group of inventions relates to medicine and can be used for modification of eating behaviour in a subject. For this purpose peripheral introduction of PYY in an amount, efficient for achieving physiological levels of PYY3-36 in blood, plasma and serum, determined after food intake, is performed; or performed is peripheral introduction of PYY agonist in an amount, efficient for imitation of physiological levels of PYY3-36 in blood, plasma or serum, determined after food intake with modification of eating behaviour, by reducing intake of calories, food consumption or appetite reduction or increase of energy consumption in the subject. Also claimed is application of PYY or its agonist as an active ingredient in production of medication. |
 Preparation for involving originating from bone marrow pluripotent stem cell into peripheral blood flow / 2519714Invention relates to chemical-pharmaceutical industry and represents a preparation for involving a mesenchymal stem cell of the bone marrow into peripheral blood from the bone marrow, which is introduced into the blood vessel or muscle and which contains any of components: (a) protein HMGB1; (b) HMGB1 protein-secreting cell; (c) a vector, into which HMGB1 protein-coding DNA is inserted; (d) protein HMGB2; (e) HMGB2 protein-secreting cell; (f) a vector, into which HMGB2 protein-coding DNA is inserted; (g) protein HMGB3; (h) HMGB3 protein-secreting cell; and (i) a vector, into which HMGB3 protein-coding DNA is inserted. |
 Method for reducing eosinophil count / 2519227Invention refers to medicine, namely immunology, and may be used for reducing eosinophil count in a human body. That is ensured by the parenteral administration of approximately 0.01 mg/kg to approximately 0.25 mg/kg of a monoclonal chimeric humanised antibody or a human antibody which binds to IL-5P and contains an immunoglobulin Fc fragment and is fucose-free; the administered antibody reduces the peripheral blood circulating eosinophil count below the detection threshold, and the circulating eosinophil calculation level remains below the detection threshold for approximately 28 days after antibody dosing. |
![Medication, inhibiting na+/h+-exchange, and halogenides of 1-dialkylaminoethyl-3-[substituted(disubstituted)phenacyl]-2-aminobenzimidazolium](http://img.russianpatents.com/img_data/1026/10268010-s.gif) Medication, inhibiting na+/h+-exchange, and halogenides of 1-dialkylaminoethyl-3-[substituted(disubstituted)phenacyl]-2-aminobenzimidazolium / 2518741Invention relates to field of pharmacology and medicine and deals with application of halogenides of 1,3-disubstituted 2-aminobenzimidazolium, of general formula I as inhibitors of Na+/H+-exchange, as well as novel 1,3-disubstituted halogenides of 2- aminobenzimidazolium. |
 Isolated polypeptide and using it for treating malignant disease and stimulating immune system, pharmaceutical composition containing such polypeptide and method of treating cancer / 2518236Invention refers to biotechnology and concerns an isolated polypeptide, a pharmaceutical composition containing such polypeptide, as well as a method of treating cancer. The presented polypeptide contains an amino acid sequence corresponding to SEQ. ID. NO: 2 or SEQ ID NO: 4. There are also characterised fragments or versions of the presented polypeptide. |
 Novel bicyclic heterocyclic compound / 2518073Claimed invention relates to novel compound of formula (1) or its pharmaceutically acceptable salt, possessing SNS inhibiting properties. In general formula |
 Prolyl hydroxylase inhibitors / 2518071Invention relates to compound of formula |
|
Method for choosing management of pregnant women with placental insufficiency and foetal growth inhibition syndrome / 2517374 Blood is examined for angiogenic factors, namely soluble fms-like tyrosine kinase (sFlt-1) and placental growth factor (PIGF). An angiogenic factor (Ka) is calculated by formula: Ka=sFlt-1/PlGF×10. If Ka is 10 or less, the pregnant woman is stated to require no admission to hospital, no case follow-up; doctor's appointments are scheduled. If Ka falls within the range of 10 to 50, the pregnant woman is admitted to hospital, wherein foetal monitoring, Doppler monitoring are performed; an amniotic fluid index (AFI) is calculated; a therapy aiming at the uterine-placental blood flow improvement is prescribed for 10 days. The amount of infusion makes 400 ml a day. The prescribed preparations are Actovegin, Trental, Instenon, Carnitini chloridum. Control ultrasonography, Doppler monitoring, foetal monitoring, AFI and Ka measurements are performed 2 weeks later. The pregnant woman is discharged from hospital if observing no negative trends. If Ka falls within the range of 50 to 100, the pregnant woman is admitted to hospital, wherein foetal monitoring, Doppler monitoring are performed, and AFI is measured; a therapy aiming at the uterine-placental blood flow improvement is prescribed for 14 days The amount of infusion makes 800 ml a day. The prescribed preparations are Actovegin, Trental, Instenon, Carnitini chloridum. Control Doppler monitoring and foetal monitoring are performed every 3 days; 2 weeks later control Ka is measured. If the trend is positive, the pregnant woman may be discharged from hospital, while no positive trend requires another 2 weeks of the therapy. If Ka is 100 or more, but less than 150, the pregnant woman is admitted to hospital, wherein foetal monitoring, Doppler monitoring are performed, and AFI is measured; a therapy aiming at the uterine-placental blood flow improvement is prescribed for 14 days. The amount of infusion makes not less than 800 ml a day with the same preparations prescribed. Those are added with the preparations for homeostasis correction, including Fraxiparine, Fragmin, Clexane optionally. Control Doppler monitoring and foetal monitoring are daily. Hypamnion also requires measuring control AFI. If a gestational age is less than 34 weeks, respiratory distress syndrome (RDS) should be prevented by administering the preparation Dexon 24 mg according to the schedule: 6 mg every 12 hours 4 times. Control Ka is necessarily measured after 2 weeks of the treatment. If the trend is positive, the pregnant woman may be discharged from hospital, while no positive trend requires another 2 weeks of the therapy. If Ka is 150 or more, and the gestational age is more than 34 weeks, the therapeutic approach is the same, as for Ka being within 100 to 150, control Doppler monitoring, foetal monitoring are performed twice a day, as well as measuring AFI. If observing no foetal weight gain for 2 weeks of the therapy or the functional state of the foetus deteriorates, a Cesarean section is performed. If the gestational age is 34-36 weeks, the therapeutic approach and follow-up are the same as for the gestational age of 34 weeks, except for the prevention of foetal RDS. However, if observing the deterioration of a foetal movement pattern or the functional status of the foetus, a Cesarean section is performed according to the foetal monitoring and Doppler monitoring findings. If the gestational age is more than 36 weeks, and Ka is 150 or more, pre-mature delivery is applied. |
|
Using 5-aminolevulinic acid and derivatives thereof in solid form for photodynamic treatment and diagnostics / 2521228 Present invention refers to a solid pharmaceutical product for oral administration which contains a photosensitiser representing a compound of general formula I: |
|
Composition for treating and preventing osteoarthritis, osteoporosis and osteoarthrosis / 2521227 Composition for treating and preventing osteoarthritis and osteoarthrosis contains a powder or an extract of a dry plant specified in a group: burdock, dandelion, cowberry, birch, St.-John's wort, golden-rod, nettle, peppermint, licorice, cinquefoil, tormentil, brier, Greek valerian, valerian, corn, holy thistle, oat, agrimony, everlasting flower, ginseng, sage, starwort, squash, willow, wild strawberry, chicory, wheat-grass, Jerusalem artichoke, bilberry, marigold, horse radish, garlic, aspen, knotgrass, plantain, inula, Fagopyrum rubricaulis, chamomile flowers, balm lemon, blue poppy, cudweed, tripartite bur-marigold; a male larval bee lyophilisate and a quercetine or dihydroquercetine, or rutin powder in certain proportions. |
|
Water-soluble bactericidal reparative composition / 2521209 Composition includes a bactericidal substance - catapol - in amount of 2.1-2.5 wt %, zosterin in amount of 1.1-5.0 wt % and distilled water. |
|
Method of treating apical periodontitis / 2521204 Method of treating apical periodontitis involves necrectomy from root canals, mechanical treatment thereof, root canal widening with multiple administration of a solution therein, insertion of a drain sponge wetted with the solution into the root canals left until the next doctor's appointment, root canal orifice closure with a dressing, root canal opening 48 hours later, dressing removal from the root canals, processing with 2% aqueous sodium hypochlorite, and gutta-percha filling. Mechanical treatment involves multiple introduction of a butol solution; mechanical treatment is followed by inserting drain sponges wetted in the butol solution into the root canals, or by introducing mixed zinc sulphate cement with butol with using a root canal filling instrument. |
|
Method for dental restoration and method for making restoration material / 2521195 Group of inventions refers to medicine, namely to dentistry, and may be used for making a restoration material used for partial dental restoration in the oral cavity. That is ensured by placing the first cell mass formed by mesenchymal or epithelial cells/cell and a second cell mass formed by other mesenchymal or epithelial cells/cell on a carrier. One of the mesenchymal or epithelial cells is made from a dental germ, and the above cell masses are placed in tight contact to each other, but not mixed. The above cell masses are grown to form the whole restored tooth or its germ. That is followed by localising the whole restored tooth or its germ grown that enables implanting the whole restored tooth or is germ within the lost tooth so that a dental crown is directed inside the oral cavity with the dental germ or the tooth being used as the restoration material for preparing an equivalent of the lost tooth within the lost tooth area. |
|
Matrix for cell transplantology / 2521194 Invention refers to cell transplantology and tissue engineering, and describes a matrix, a basic element of which is a flat plate made from a spatially cross-linked hydrophobic polymer containing hydrophilic groups and forming on the plate surface a layer of saturated hydrocarbons having a chain length of 8 to 16 carbon atoms and directed preferentially along the normal line to the plate surface. The spatially cross-linked polymer is formed on substrates by exposing a photopolimerisable composition containing oligourethane methacrylate, a methacrylate monomer having a chain length of 8 to 18 carbon atoms, 2,2-dimethoxy-2-phenylacetophenone and 2,4-ditertbutylorthquinone, to light at a wave length of 320-380 nm. |
|
Tubule-closing materials from silicon dioxide for tooth care preparations / 2520747 Group of inventions relates to precipitated materials from silicon dioxide for application as abrasive substances or thickening agents in preparations for tooth care, which are simultaneously efficient for closing dentinal tubules in order to reduce dentin sensitivity. The claimed precipitated material from silicon dioxide has an average size of particles from 1 to 5 microns and contains a metal adduct, present on at least a part of its surface for formation of a metal adduct-processed precipitated material from silicon dioxide, which demonstrates more than 10% reduction of zeta-potential in comparison with precipitated material from silicon dioxide of the same structure but without the metal adduct. Also claimed are: versions of tooth care preparation, containing the said precipitated material from silicon dioxide and a method of processing teeth of a mammal with application of such preparations. |
|
Therapeutic composition for treating bronchitis and method for preparing it / 2520745 Invention refers to the pharmaceutical industry, particularly to a pharmaceutical composition for treating bronchitis. The pharmaceutical composition for treating bronchitis contains a SCUTELLARIAE RADIX powder; an essence of mixed CITRI RETICULATAE PERICARPIUM and CINNAMOMI RAMULUS; a concentrated aqueous extract of herbal residue of the essence process, and mixed ATRACTYLODIS MACROCEPHALAE RHIZOMA, PORIA, GLYCYRRHIZAE RADIX ET RHIZOMA, FARFARAE FLOS, FORSYTHIAE FRUCTUS; a concentrated ethanol extract of PINELLIAE RHIZOMA, PERILLAE FRUCTUS, SINAPIS SEMEN, RAPHANI SEMEN, ASTERIS RADIX ET RHIZOMA, HOUTTUYNIAE HERBA, ARMENIACAE SEMEN AMARUM. |
|
Wetting agent for skin and using it / 2520743 Invention refers to the cosmetic industry, namely a wetting agent for the skin. A wetting composition for the skin containing water, glycerol, butyrospermum parki, cyclopentasiloxane, a sodium pyrrolidone carboxylic acid, panthenol, demethiconol, optionally sodium polyacrylate taken in certain proportions, as well as fatty ingredients, an emulsion stabiliser, a preserving agent and/or a pH adjuster. Using the composition for hydration or moistening of the skin in need thereof. Using the composition for the skin hydration for the first two hours after application. A method for the skin hydration. |
|
Method of treating spinal malignant tumours and spinal metastases of tumours / 2520682 Invention refers to medicine, namely to oncology and radiotherapy, and may be used for treating patients with spinal malignant tumours and spinal metastases of tumours accompanied by anticipated or complicated spinal disorders. That is ensured by introducing bone cement into the tumour growth centres. The bone cement formulation is specified so that its polymerisation is accompanied by generating heat sufficient to provide thermal sensibilisation of the tumour cells, and β- and γ-radionuclides are added to the cement. |
 Amino acid preparation eliciting antitumor effect and method for its preparing / 2245143Invention relates, in particular, to the development of an antitumor preparation based on natural substances. Invention relates to an amino acid preparation comprising at least one modified essential amino acid obtained by treatment of amino acid by ultraviolet radiation (UV) at wavelength 250-350 nm for 12-80 h at temperature 15-30oC or with ozone at temperature 15-25oC. The modified amino acid has no toxicity for health cells. Also, invention relates to a method for preparing such preparation. Invention provides the development of an antitumor preparation based on modified amino acids and expanded assortment of antitumor preparations being without cytotoxicity for normal cells. |
FIELD: medicine.
SUBSTANCE: what is used is a 20% alcoholic tincture (1:10) of medicinal herbs in the following weight proportions: Rhaponticum carthamoides roots and rhizomes - 2, tormentil roots - 1, peppermint leaves - 3. A mouthwash is prescribed before a dentist's appointment for 3-4 days 3 times a day, as well as 10-15 minutes before an impression manipulation.
EFFECT: method provides reducing intensity a gag reflex accompanying dental manipulations.
The invention relates to medicine and can be used in the practice of dentistry.
Nausea and vomiting are nonspecific manifestations of physiological reactions in response to different types of stimuli coming from both outside and inside the body. These phenomena are necessary for the adequate operation and maintenance of the internal environment of the body. However, there are increased nausea and vomiting, generating considerable hardship and human suffering.
The manifestation of heightened gag reflex often creates difficulties for dentists. Particularly acute this problem affects removable media devices.
The classic stages of treatment of patients in need of removable devices may not be performed at a decent level because of the increased level of gag reflex. The principles of reducing the level of heightened gag reflex inherent in the reduction of afferent activity in the emetic center, located in the dorsolateral part of the reticular formation in the medulla [1, 2].
This condition is achieved pharmacologically by the application of certain groups of drugs: antiserotonin, phenothiazines, butyrophenones, antihistamines, anticholinergic, benzamide, antidepressants [3]. However, all these drugs have severe side effects. Can in order to predict extrapyramidal disorder significant sedation, dry mouth, visual disturbances, memory loss, disorientation and hallucinations, abnormal heart rhythm, and others [4].
There is a method of reducing the level of heightened gag reflex on dental reception, patent No. 2437670, which is the use of tools, has antiemetic effect with simultaneous anti-inflammatory, capillary, reparative, anti-microbial actions. The drug is a 20%alcohol tincture of the plant collection of the following composition: rhizome with the roots of leuzea 2 mass parts, rhizome cinquefoil panostaja 1 mass part, peppermint leaves 1 mass part.
Tincture is a liquid light-brown, slightly astringent taste, with specific pleasant smell. To receive infusions of 100 g of vegetable raw materials were crushed to a particle size of 2-3 mm, were placed in percolator and get 20%ethyl alcohol to obtain 1 liter of infusion [5].
The purpose of the invention to create a method of reducing a level of heightened gag reflex that occurs when taking impressions in the dental appointment.
Goal is achieved by treatment with antiemetic effect with simultaneous anti-inflammatory, capillary, reparative, anti-microbial is astiani, before visiting a dentist within 3-4 days 3 times a day in the form of a mouth rinse, as well as for 10-15 minutes before the procedure of taking impressions. The drug is a 20%alcohol tincture of the plant collection of the following composition: rhizome with the roots of leuzea - 2 mass parts, rhizome cinquefoil panostaja - 1 mass part, peppermint leaves - 3 mass parts.
Tincture is a liquid light-brown, slightly astringent taste, with specific pleasant smell. To receive infusions of 100 g of vegetable raw materials were crushed to a particle size of 2-3 mm, were placed in percolator and get 20%ethyl alcohol to obtain 1 liter of brandy.
Differences from the prototype are in a special assignment scheme funds, namely: before visiting a dentist within 3-4 days 3 times a day in the form of a mouth rinse, as well as for 10-15 minutes before the procedure of taking impressions. Presents the scheme of the claimed solution provides early suppression of the sensitivity of the receptors of the oral cavity and leads to a sustainable reduction of the level of heightened gag reflex. Another feature is the increased content in the composition of the mass fraction of peppermint leaves, providing local irritant action and contribute to the reduced sensitivity is titelliste receptors of the oral cavity and reduce afferention with them. These features of the method of reducing the level of heightened gag reflex can achieve significant improvement in the quality of care at the dental appointment.
Example 1. Patient Doctor turned to the dental clinic with complaints about the lack of teeth on the upper and lower jaws. After examination, she was diagnosed with partial absence of teeth in the upper jaw 1 class, partial absence of teeth in the lower jaw 3 class. During the survey identified trigger zone of heightened gag reflex, located on the soft palate on the right and left. During orthopedic treatment was applied the method to reduce the level of heightened gag reflex on the dental admission. Clinical stages of orthopedic treatment were successful. The treatment outcome is positive, the Outlook is positive.
Example 2. The patient And. turned to the dental clinic with complaints about the complete absence of teeth on the upper jaw. History of earlier attempts orthopedic treatment, which had no success due to the presence of heightened gag reflex. After examination, she was diagnosed with complete absence of teeth in the upper jaw. It was recommended the construction of complete removable denture on the upper jaw. Before treatment was applied the method of reducing the level of high rotdog the reflex on the dental admission. During the treatment manipulations were carried out rinsing the mouth by means of reducing the level of heightened gag reflex on the dental admission. After this combined treatment level gag reflex decreased to normal levels. The treatment outcome is positive, the Outlook is positive.
Example 3. Patient R. turned to the dental clinic with complaints about the lack of teeth in the upper jaw. Notify your doctor about the increased gag reflex, shown previously in dentistry. After examination, she was diagnosed with partial absence of teeth in the upper jaw 1 class. It was recommended to make a clasp denture in the upper jaw. Before treatment were used way to reduce the level of heightened gag reflex on the dental admission. All procedures were performed without difficulty. The level of gag reflex decreased to the optimum level. The treatment outcome is positive, the Outlook is positive.
Thus, the claimed method can significantly reduce the level of gag reflex when performing dental procedures with concurrent analgesic, anti-inflammatory, reparative, anti-microbial, capillary effects. Other negative side effects were not noted.
Sources in the information
1. Burov N.E. Nausea and vomiting in clinical practice (etiology, pathogenesis, prevention and treatment) // Russian medical journal. - 2002. - Volume 10. No. 8-9. - P.390-395.
2. Yakovenko UP Vomiting and nausea: pathogenesis, etiology, diagnosis, treatment / Epekeina, Plagiari, Niagaranew [and other] // Farmateka. - 2005. No. 1. - P.58-61.
3. Martirosov K.S. Experimental study of the role of blockade of 5-NTZ-serotonin receptors and Dz dopamine receptors in the mechanism of occurrence of early radiation vomiting in monkeys / Cosmeticos, Uggeri, Try [and other] // Radiation biology. Radioecology. - 2000. Volume 40. No. 3. - S-280.
4. Kolmakova OS, the performance took place AA Nausea and vomiting: an algorithm for diagnosis and treatment / Russian journal of gastroenterology, Hepatology, Coloproctology. - 2000. No. 4. - P.28-32.
5. The way to reduce excess gagging on dental reception / Wondermega, Lphabetic, Tab // Patent No. 2437670.
The way to reduce the level of heightened gag reflex in a patient on the dentist, which consists in the fact that the patient rinses the oral cavity within 3-4 days 3 times a day and once for 10-15 minutes prior to therapeutic manipulation 20%alcohol tincture (1:10), obtained from the collection of medicinal plants, taken in the following mass parts: rhizome with the roots of leuzea -2, rhizome cinquefoil panostaja - 1, leaf, peppermint leaf - 3.